

Everardo D Saad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9115278/publications.pdf>

Version: 2024-02-01

57
papers

1,665
citations

304743

22
h-index

289244

40
g-index

57
all docs

57
docs citations

57
times ranked

2150
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2007, 99, 592-600.	6.3	279
2	Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1958-1962.	1.6	148
3	Potential for drug interactions in hospitalized cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 286-290.	2.3	132
4	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. <i>Value in Health</i> , 2017, 20, 487-495.	0.3	101
5	Incidence and Severity of Hand-Foot Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-Institution Experience. <i>Cancer Investigation</i> , 2002, 20, 3-10.	1.3	93
6	VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 312-324.	0.5	69
7	Overall Survival: Patient Outcome, Therapeutic Objective, Clinical Trial End Point, or Public Health Measure?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1750-1754.	1.6	63
8	Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 451-453.	1.3	61
9	Precision medicine needs randomized clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 317-323.	27.6	60
10	Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. <i>Lancet Oncology</i> , 2019, 20, 361-370.	10.7	59
11	Phase I Study of Preoperative Oral Uracil and Tegafur Plus Leucovorin and Radiation Therapy in Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 3529-3534.	1.6	57
12	A Systematic Review on Drug Interactions in Oncology. <i>Cancer Investigation</i> , 2006, 24, 704-712.	1.3	49
13	Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 833-842.	5.0	48
14	Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?. <i>Journal of the National Cancer Institute</i> , 2018, 110, 232-240.	6.3	40
15	Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies. <i>Journal of Clinical Oncology</i> , 2011, 29, 4719-4720.	1.6	33
16	Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. <i>Drugs</i> , 2017, 77, 713-719.	10.9	33
17	Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 516-516.	46.4	32
18	Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy. <i>Oncologist</i> , 2022, 27, 266-271.	3.7	29

#	ARTICLE	IF	CITATIONS
19	Non-inferiority trials in breast and non-small cell lung cancer: Choice of non-inferiority margins and other statistical aspects. <i>Acta Oncologica</i> , 2012, 51, 890-896.	1.8	25
20	Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trials. <i>Cancer Treatment Reviews</i> , 2012, 38, 807-814.	7.7	25
21	Molecular-Targeted Agents in Pancreatic Cancer. <i>Cancer Control</i> , 2004, 11, 32-38.	1.8	24
22	Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. <i>Cancer Treatment Reviews</i> , 2012, 38, 554-558.	7.7	23
23	The impact of data errors on the outcome of randomized clinical trials. <i>Clinical Trials</i> , 2017, 14, 499-506.	1.6	15
24	Sample Size Calculation in Oncology Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 570-574.	1.3	14
25	Case Report: Hand-Foot Syndrome Induced by the Oral Fluoropyrimidine S-1. <i>Japanese Journal of Clinical Oncology</i> , 2001, 31, 172-174.	1.3	12
26	Increasing output and low publication rate of Brazilian studies presented at the American Society of Clinical Oncology Annual Meetings. <i>Clinics</i> , 2008, 63, 293-296.	1.5	12
27	Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1619-1627.	1.1	11
28	Treatment priorities in oncology: do we want to live longer or better?. <i>Clinics</i> , 2014, 69, 509-514.	1.5	11
29	Brazilian Abstracts Presented at the American Urological Association Annual Meetings: Contribution, Publication Rates, and Comparison with Oncology Abstracts. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2014, 40, 730-737.	1.5	10
30	Chemotherapy of metastatic colorectal cancer. <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 239-247.	0.8	9
31	Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer. <i>Cancer Treatment Reviews</i> , 2016, 50, 194-199.	7.7	9
32	Central statistical monitoring of investigator-led clinical trials in oncology. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1207-1214.	2.2	9
33	Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 205-211.	4.4	6
34	Targeted drugs in oncology: New names, new mechanisms, new paradigm. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 1233-1243.	1.0	6
35	Formal Statistical Testing and Inference in Randomized Phase II Trials in Medical Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 143-145.	1.3	6
36	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	5.9	6

#	ARTICLE	IF	CITATIONS
37	The Net Benefit of a treatment should take the correlation between benefits and harms into account. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 148-158.	5.0	6
38	Endpoints in advanced breast cancer: methodological aspects & clinical implications. <i>Indian Journal of Medical Research</i> , 2011, 134, 413-8.	1.0	5
39	UFT and Oral Leucovorin as Radiation Sensitizers in Rectal and Other Gastrointestinal Malignancies. <i>Cancer Investigation</i> , 2003, 21, 624-629.	1.3	4
40	Living better or living longer? Perceptions of patients and health care professionals in oncology. <i>Ecancermedicalsecience</i> , 2015, 9, 574.	1.1	4
41	Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question. <i>JAMA Oncology</i> , 2017, 3, 416.	7.1	4
42	Assessment of quality of life in phase III trials of radiotherapy in localized or locally advanced head and neck cancer over the past 17 years. <i>Annals of Palliative Medicine</i> , 2017, 6, 73-80.	1.2	4
43	Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer. <i>Revista Da Associação Médica Brasileira</i> , 2010, 56, 22-26.	0.7	3
44	Estudos Brasileiros Apresentados nos Encontros Anuais da ASCO entre 2001 e 2007: Aumento de Produções, com Baixa Taxa de Publicações. <i>Revista Brasileira De Cancerologia</i> , 2019, 55, 221-227.	0.3	3
45	Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3442.	3.7	2
46	Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3538-3538.	1.6	2
47	Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3578-3578.	1.6	2
48	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	6.3	2
49	Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors". <i>Drugs</i> , 2017, 77, 1139-1140.	10.9	1
50	Meta-Research on Oncology Trials: A Toolkit for Researchers with Limited Resources. <i>Oncologist</i> , 2018, 23, 1467-1473.	3.7	1
51	Brazilian Validation of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (QLG) Computerised Adaptive Tests (CAT) Core. <i>Current Oncology</i> , 2021, 28, 3373-3383.	2.2	1
52	Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2015, 33, 666-666.	1.6	1
53	JCOG0603: Are We Really Sure This Was a Negative Trial?. <i>Journal of Clinical Oncology</i> , 2022, 40, 803-805.	1.6	1
54	Commentary on Bamat et al.. <i>Clinical Trials</i> , 2020, 17, 560-561.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncology. Expert Review of Precision Medicine and Drug Development, 2021, 6, 271-280.	0.7	0
56	Meta-Research in Oncology. , 2018, , 307-314.		0
57	Superiority and Non-inferiority Phase III Oncology Trials. , 2018, , 203-216.		0